• I-BET-762: Transforming BET Inhibition for Translational Imp

  2026-06-08

  This article delivers a strategic, evidence-driven perspective on I-BET-762 as a next-generation BET inhibitor, weaving new mechanistic insights from recent ferroptosis research with practical guidance for translational scientists. By contextualizing I-BET-762's unique selectivity and potency in anti-inflammatory and cancer models, and by translating recent BRD4-ferroptosis synergy findings, it provides actionable recommendations and protocol parameters. The discussion goes beyond typical product pages by critically comparing workflows, highlighting competitive positioning, and addressing the limitations and future vision for BET inhibitor deployment in preclinical and translational research.

• RG108 (SKU A1913): Reliable DNMT Inhibition for Epigenetic A

  2026-06-08

  This article provides scenario-driven, evidence-based guidance on using RG108 (SKU A1913), a potent DNA methyltransferase inhibitor, to address real laboratory challenges in cell viability, proliferation, and cytotoxicity assays. By integrating literature-backed data and practical protocol insights, it demonstrates how RG108 enhances reproducibility and precision in epigenetic research workflows.

• Co-Targeting BRD4 and RAC1 Disrupts Oncogenic Networks in Br

  2026-06-07

  This study demonstrates that dual inhibition of BET bromodomain BRD4 and RAC1 in various breast cancer subtypes suppresses tumor growth and stemness by dismantling the c-MYC–G9a–FTH1 axis and downregulating HDAC1. These findings highlight a mechanistically distinct epigenetic intervention strategy with translational implications for overcoming tumor heterogeneity.

• Adefovir Pharmacokinetics in Transporter Phenotyping Cocktai

  2026-06-06

  This study applies population pharmacokinetic modeling to clarify how Adefovir behaves as a probe for renal OAT1 function within a clinical transporter cocktail. The findings reveal that while co-administered drugs modestly alter absorption parameters, renal elimination—a key metric for OAT1 activity—remains robust, supporting Adefovir’s continued use in phenotyping studies.

• SP2509: Potent Lysine-Specific Demethylase 1 Antagonist for

  2026-06-05

  SP2509 is a highly selective Lysine-specific demethylase 1 antagonist showing sub-nanomolar potency in AML models. It disrupts LSD1 function, induces apoptosis, and promotes differentiation in acute myeloid leukemia cells. This dossier summarizes validated mechanisms and optimal research use.

• Mitochondrial Calcium Signaling Suppresses Ferroptosis in Ca

  2026-06-05

  This study uncovers a mechanistic link between mitochondrial calcium uptake and the suppression of ferroptotic cell death in cancer cells, mediated by acetyl-CoA-dependent regulation of GPX4. The findings suggest new angles for understanding cell survival in tumors and offer a framework for targeting ferroptosis in cancer research.

• Anlotinib Hydrochloride: Superior Multi-Target Angiogenesis

  2026-06-04

  This study demonstrates that anlotinib hydrochloride is a potent multi-target tyrosine kinase inhibitor, effectively suppressing angiogenesis by targeting VEGFR2, PDGFRβ, and FGFR1. The findings highlight its superior efficacy compared to established anti-angiogenic agents, providing compelling evidence for its application in advanced cancer research.

• Romidepsin (FK228): Precision HDAC Inhibition in Spliceosome

  2026-06-04

  Explore how Romidepsin (FK228) enables advanced epigenetic modulation and spliceosome-targeted research in cancer biology. This article uniquely bridges HDAC inhibition, alternative splicing, and practical assay optimization, offering insights not found in standard Romidepsin protocols.

• GSK343 EZH2 Inhibitor: Protocol Advances for Epigenetic Canc

  2026-06-03

  GSK343 is a highly selective and cell-permeable EZH2 inhibitor, purpose-built for dissecting PRC2-mediated H3K27me3 in cancer epigenetics. This article translates emerging findings and real-world workflows into actionable guidance, maximizing the utility of GSK343 from APExBIO for robust, reproducible results in breast, prostate, and stem cell research.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-06-03

  The referenced study demonstrates that BRD4 inhibitors, including I-BET-762, broadly sensitize diverse cancer cell lines to erastin-induced ferroptosis by promoting reactive oxygen species (ROS) accumulation and downregulating FSP1. These mechanistic insights clarify the role of BET inhibition in ferroptosis regulation and highlight actionable strategies for cancer research.

• Valemetostat (DS-3201): Protocols & Precision for EZH2 Mutan

  2026-06-02

  Valemetostat (DS-3201) is redefining epigenetic cancer therapy with its dual EZH1/EZH2 inhibition, offering unmatched selectivity and efficacy in relapsed/refractory lymphoma models. This article provides a stepwise guide to experimental workflows, advanced troubleshooting, and actionable insights for maximizing the compound’s translational impact in lymphoma research.

• Dual SMAD and Wnt Inhibition Enables Robust iPSC-RGC Differe

  2026-06-02

  This study presents a chemically defined protocol using dual SMAD and Wnt pathway inhibition to achieve efficient, reproducible differentiation of human iPSCs into retinal ganglion cells (RGCs) exceeding 80% purity. The approach addresses long-standing challenges in RGC modeling for glaucoma and neurodegenerative disease research, providing a foundation for more consistent disease modeling and therapeutic screening.

• EZH2 Inhibitors in HPV-Associated Cervical Cancer: Mechanist

  2026-06-01

  This study investigates the effects of EZH2 inhibitors, including EPZ-6438, on HPV-associated cervical cancer. It demonstrates that selective EZH2 blockade suppresses oncogenic HPV gene expression and promotes tumor suppressor pathways, offering a promising alternative to conventional chemotherapy.

• Nicotinamide Riboside Chloride (NIAGEN): Precision NAD+ Modu

  2026-06-01

  Unlock the latest advances in metabolic and neurodegenerative disease research with Nicotinamide Riboside Chloride (NIAGEN). Discover how precision NAD+ modulation supports robust retinal ganglion cell models and translational breakthroughs beyond standard methodologies.

• Balancing Self-Renewal and Differentiation in Human Intestin

  2026-05-31

  This study presents a tunable human intestinal organoid system that achieves a controlled balance between stem cell self-renewal and differentiation using small molecule pathway modulators. The innovation increases cellular diversity and proliferative capacity in organoids, enhancing their utility for disease modeling and high-throughput applications.

16718 records 1/1115 page Next 12345 下5页 Last page